Evaluation of the diagnostic potential of CD1a immunohistochemistry for visceral leishmaniasis by Gadelha, Sami de Andrade Cordeiro et al.
Rev Inst Med Trop São Paulo. 2019;61:e25 Page 1 of 5
BRIEF COMMUNICATION
http://doi.org/10.1590/S1678-9946201961025
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
1Universidade Federal do Ceará, Faculdade 
de Medicina, Departamento de Patologia e 
Medicina Legal, Fortaleza, Ceará, Brazil
2Instituto do Câncer do Ceará, Hospital 
Haroldo Juaçaba, Fortaleza, Ceará, Brazil
3Hospital Infantil Albert Sabin, Fortaleza, 
Ceará, Brazil
Correspondence to: Sami de Andrade 
Cordeiro Gadelha 
Universidade Federal do Ceará, Faculdade 
de Medicina, Departamento de Patologia e 
Medicina Legal, Rua Monsenhor Furtado, 
Rodolfo Teófilo, CEP 60441-750, Fortaleza, 
CE, Brazil 
Tel: +55 85 33668301 
Fax: +55 85 33668300
E-mail: samigadelha@gmail.com
Received: 28 November 2018
Accepted: 2 April 2019
Evaluation of the diagnostic potential of CD1a 
immunohistochemistry for visceral leishmaniasis
Sami de Andrade Cordeiro Gadelha1, Maria do Perpétuo Socorro Saldanha 
da Cunha2,3, Gabriela Maia Coelho1, Tamises Melo Siqueira Marinho1, Carlos 
Gustavo Hirth1,2,3
ABSTRACT
Visceral Leishmaniasis is a public health problem caused by protozoans of the genus 
Leishmania. K39 serological test is commonly used in the initial investigation, with high 
specificity, but variable sensitivity. Amastigotes can be identified by optical microscopy, 
however, the differential diagnosis with cellular debris or other intracellular parasites is 
necessary. Recent studies have raised the possibility of using immunohistochemistry in the 
diagnosis of visceral leishmaniasis with labeling of amastigotes by the anti-CD1a antibody. 
This retrospective study was based on 38 samples from patients with visceral leishmaniasis 
whose diagnoses were confirmed by myelogram and/or k39 testing, aside from positive 
(N=13) and negative biopsies (N=25), 2 samples from patients with false positive biopsies 
for visceral leishmaniasis and 8 samples from patients with histoplasmosis diagnosis. The 
histological slides were evaluated for the presence of amastigotes and their Modified Ridley 
Parasitic Index. The samples were submitted to immunohistochemical reactions using the 
anti-CD1a antibody with MTB1 and O10 clones. Immunohistochemical reactions with 
MTB1 and O10 clones had low sensitivity in this study. However, all bone marrow samples 
were previously decalcified with nitric acid which is probably a deleterious treatment for 
immunohistochemical reactions in this site. Excluding these samples, we obtained 58.33% 
sensitivity and 100% specificity with the MTB1 clone. Despite the intermediate sensitivity, the 
immunohistochemistry for the CD1a marker with clone MTB1 can be useful in the differential 
diagnosis of visceral leishmaniasis, helping to discriminate leishmania amastigotes from 
other pathogens with similar morphology and cellular debris in different samples, except in 
bone marrow biopsies previously decalcified with nitric acid.
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INTRODUCTION
Visceral leishmaniasis is a growing public health problem in America, Asia, 
Europe and Africa. Its importance led the World Health Organization (WHO) to 
include it among the six priority diseases in the control program of this institution1. 
According to the Brazilian Ministry of Health, in 19 years of notification (1984-
2002), visceral leishmaniasis totaled 48,455 cases and approximately 66% occurred 
in the Bahia, Ceara, Maranhao and Piaui States2. The etiological agents of visceral 
leishmaniasis are protozoans of the genus Leishmania, exclusively intracellular 
parasites of the mononuclear phagocytic system cells, with a flagellate or 
promastigote form found in the digestive tract of the insect vector and an aflagellate 
or amastigote form within vertebrate tissues3. Most infections are clinically 
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diagnosed. Patients usually presents with fever, cutaneous-
mucosal pallor, hepatosplenomegaly andpancytopenia3.
Serological tests are the most commonly used 
complementary diagnostic methods3. The rapid rK39 
antigen-based immunochromatographic test Kalazar 
Detect(r), or K39 test, is a qualitative test of serum 
antibodies against the recombinant antigen K39 of 
Leishmania chagasi species, has high specificity (100%), 
however its sensitivity is variable in different countries4. In 
addition, one can identify parasites of the genus Leishmania 
by optical microscopy3. Peripheral blood smears are easily 
collected, however, there are few circulating parasite 
cells3. Myelogram, a bone marrow aspirate analysis, is a 
frequently used method3. Direct visualization of amastigotes 
by biopsies of bone marrow, liver, lymph node and other 
visceral organs is a valid method, especially in cases with 
high parasitic load3. In biopsies, the differential diagnosis 
between amastigotes and cell debris within macrophages 
is necessary as it is a common finding in hemophagocytic 
syndromes and in native neoplasms or metastases with 
bone marrow involvement5, clinical conditions potentially 
mimicking visceral leishmaniasis6. Another challenge for 
the morphological diagnosis of amastigotes by optical 
microscopy is to differentiate them from other intracellular 
parasites such as the Histoplasma capsulatum fungus which 
has similar morphology and involvement of lymph nodes, 
liver, spleen and bone marrow7. Recent studies have raised 
the possibility of using immunohistochemistry to aid in 
the parasitological diagnosis of leishmaniasis with the 
labeling of amastigotes by the anti-CD1a antibody, clone 
MTB1, but mainly in cutaneous leishmaniasis, with few 
studies exploring this possibility in the context of visceral 
leishmaniasis. A study has demonstrated this in all 19 cases 
of cutaneous leishmaniasis caused by Leishmania infantum, 
in addition to finding positivity in all four cases of visceral 
leishmaniasis8. However, the small number of visceral 
leishmaniasis samples tested in this study is noteworthy.
The CD1a antigen is a transmembrane glycoprotein 
present in the plasma membrane of dendritic cells and 
thymocytes, structurally related to molecules of the Major 
Histocompatibility Complex (MHC)9. Some hypotheses 
have been proposed to justify the labeling of amastigotes by 
an antibody against a dendritic cell surface antigen. Among 
them, the most accepted is that amastigotes acquire the 
CD1a surface antigen after phagocytosis by dendritic cells, 
exposing CD1a in its own surface and kinetoplast10. This 
hypothesis is reinforced by the finding that samples from 
culture media of leishmania promastigotes do not express 
CD1a, as opposed to cases of cutaneous leishmaniasis 
caused by Leishmania major amastigotes, which are 
positive for this marker11. Immunohistochemical markers 
developed for specific antigens of Leishmania sp are not 
commercially available, so that diagnostic centers have 
to develop their own markers, increasing costs due to 
standardization and all necessary procedures to minimize 
the risk of cross reactions with other protozoa belonging 
to the Trypanosomatidae family. 
Considering all the above mentioned, the use of a 
commercially available immunohistochemical marker as 
the anti-CD1a, an antibody widely used for other purposes 
such as the diagnosis of histiocytosis, could represent an 
enormous gain for different medical centers, even those 
not focused on research or diagnosis of infectious diseases.
MATERIAL AND METHODS
The present study was retrospective and based on biopsy 
specimens collected between 2006 and 2018 from patients 
diagnosed with visceral leishmaniasis or histoplasmosis, 
considering results obtained in biopsies, and/or myelograms 
or the K39 test, attended at Hospital Infantil Albert Sabin, 
Fortaleza, Ceara State; at Hospital Haroldo Juaçaba/
Instituto do Cancer do Ceara, Fortaleza, Ceara State; and 
at Hospital Universitario Walter Cantidio, Universidade 
Federal do Ceara, Fortaleza, Ceara State. This research was 
approved by the Research Ethics Committee of Hospital 
Universitario Walter Cantidio (protocol Nº 2.909.806). 
Medical notes of patients from the participating institutions 
with suspected but not conclusive diagnosis of visceral 
leishmaniasis or histoplasmosis were included in the 
study, provided that there was enough archived biopsy 
material, from bone marrow and other sites, suitable for 
immunohistochemical reactions. Patients without archived 
tissue or with insufficient tissue for analysis were excluded. 
We obtained a total of 48 cases.
Regarding the biopsy sites included in this study, a 
pathology laboratory receives various organs from patients 
under clinical investigation for a variety of conditions, 
and, sometimes, the diagnosis of visceral leishmaniasis 
was made by biopsies other than those from bone marrow. 
Medical records from patients were reviewed to evaluate 
clinical and serological diagnosis, treatment and response 
to treatment. The histological slides were reviewed for the 
presence or absence of amastigotes, associated with the 
measurement of Modified Ridley Parasitic Index, based 
on the number of parasites permicroscopic field (40x 
magnification): score 6, more than 100,000 parasites; 
score 5, between 10,000 and 100,000 parasites; score 4, 
between 1,000 and 10,000 parasites; score 3, between 100 
and 1,000 parasites; score 2, between 10 and 100 parasites; 
score 1, between 1 and 10 parasites; score 0, zero 
parasites12. Slides of all samples were stained by PAS and 
Rev Inst Med Trop São Paulo. 2019;61:e25
Evaluation of the diagnostic potential of CD1a immunohistochemistry for visceral leishmaniasis
Page 3 of 5
Grocott’s methenamine silver staining to exclude deep 
mycosis. After slide revision, special staining evaluation 
and revision of medical records, the patients were divided 
into four groups:
True positives - 13 cases with samples containing 
amastigotes in histopathology, negative results for 
mycosis according to PAS and Grocott’s methenamine 
silver staining.
False positives - 2 cases that were suggestive of visceral 
leishmaniasis by biopsy, with visualization of cellular 
debris within macrophages, but with negative myelogram 
and K39 test results. 
True negatives - 8 cases with samples containing amastigote-
like structures with positive staining by PAS and/or 
Grocott’s methenamine silver staining, characterizing 
Histoplasma capsulatum yeast cells.
False negatives - 25 cases with myelogram positive samples 
for amastigotes, but with negative biopsy samples, as 
well as patients with K39 positive results but negative by 
direct microscopy who responsed to therapy according 
to medical records.
Immunohistochemical reactions were performed using 
anti-CD1a, MTB1 (Cell Marque/Merk KGaA, Darmstadt, 
Germany) and O10 (DAKO/Agilent Technologies Inc., 
Santa Clara, CA, USA) antibody clones, after dewaxing 
and tissue treatment with the epitope recovery solutions 
PT LinkTM, following the manufacturer’s recommendations 
((DAKO/Agilent Technologies Inc., Santa Clara, CA, USA). 
Samples were incubated with the Auto Stainer Link 48TM 
(DAKO/Agilent Technologies Inc., Santa Clara, CA, 
USA) and visualized using the EnVision FlexTM polymer 
(DAKO/Agilent Technologies Inc., Santa Clara, CA, USA). 
All reactions were performed with positive and negative 
controls. Positive controls were external samples containing 
dendritic cells from skin tissue and from a lymph node 
with Langerhans cell histiocytosis. Negative controls were 
internal, constituted by fragments of the samples known 
not to express CD1a. Sensitivity, specificity and accuracy 
of the CD1a marker were calculated for the diagnosis of 
visceral leishmaniasis.
RESULTS
In immunohistochemical positive reactions amastigotes 
were labeled in a pattern of peripheral membrane-like 
reinforcement, leaving the unstained nucleus in the center 
with a reinforcement in one pole, apparently because of the 
kinetoplast staining8 (Figure 1).
Regarding the anatomical site and the Modified Ridley 
Parasitic Index, the results of immunohistochemical reactions 
are summarized in Table 1. The CD1a immunohistochemical 
reactions had low sensitivity in this study, 23.68% for MTB1 
clone and 2.63% for O10 clone. However, negative results 
were obtained in almost all bone marrow samples for both 
MTB1 (26 of 28) and O10 (27 of 28). When considering 
biopsy specimens from other sites, excluding bone marrow 
Figure 1 - Amastigotes within macrophages are observed on the left side, in a duodenal sample with a modified Ridley parasite 
index of 6 (H&E, 1000x). A slide of this same sample is shown with the immunohistochemical reaction using the clone MTB1 of CD1a 
(1000x) on the right side. At the bottom, on the right corner, an amastigote is shown in detail, stained by immunohistochemistry in a 
pattern of peripheral membrane-like reinforcement, leaving the unstained nucleus in the center, and presenting with a reinforcement 
in one pole, apparently because of the kinetoplast staining (Digitally magnified. Original 1,000X magnification).
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biopsies, we obtained, sensitivity of the MTB1 clone was 
58.33%, specificity 100% and accuracy 75%.
In respect to the O10 clone, sensitivity was 8.33%, 
specificity 87.50% and accuracy 40%. These results are 
summarized in Table 2. Two specimens with Histoplasma 
capsulatum were positive for clone O10.
DISCUSSION
Comparing the tests using MTB1 and O10 clones, 
there was greater sensitivity, specificity and, consequently, 
accuracy with the use of clone MTB1, corroborating the 
findings of other studies8,13. The immunohistochemical 
reactions using both clones were negative in the false positive 
samples, which shows that the use of immunohistochemistry 
may be relevant for the differential diagnosis between 
amastigotes present within macrophages and cellular debris.
The intermediate sensitivity obtained can be related to 
the fact that not all amastigotes will be phagocytized by 
CD1a positive cells. This antigenic exposure will only be 
possible in the papillary areas of the dermis where CD1a 
positive dendritic cells are found, so that amastigotes 
confined to deeper zones of the dermis will have lower 
chances of being exposed to CD1a. Because they multiply 
by binary fission, only amastigotes previously exposed 
to CD1a will produce more CD1a positive amastigotes8. 
Thus, one can infer that only amastigotes that descend 
from parasites previously exposed to CD1a in the skin will 
present positivity to this marker in internal organs. 
In our study, there was a striking difference in sensitivity 
between the analysis using all cases and the one excluding 
the cases in which the bone marrow was the only site of 
biopsy. In the pathology laboratories of the participating 
institutions, nitric acid is used as a decalcifier in bone 
marrow biopsy specimens, which may have denatured CD1a 
in amastigotes and caused negative immunohistochemical 
reactions despite the presence of the parasite. The fact 
that this study is retrospective, using samples already 
processed with nitric acid, did not allow us to compare the 
effect of Ethylenediaminetetraacetic acid (EDTA), another 
decalcifying agent that seems to be less deleterious for 
Table 1 - Results divided by group and stratified according to the biopsy site and Modified Ridley Parasitic Index.
Group Biopsy Site No. of cases Ridley index CD1a (O10) CD1a (MTB1)
True positives 
(amastigotes)
Spleen 1 2 Negative Negative
Duodenum 3 4-6 3 Negatives 3 Positives
Liver 2 2-3 1 Positive 1 Negative 2 Positives
Lymph node 2 3 2 Negatives 2 Positives
Bone Marrow 5 1-3 5 Negatives 2 Positives 3 Negatives
False positives 
(cellular debris within 
macrophages)
Lymph node 1 0 Negative Negative
Bone Marrow 1 0 Negative Negative
True negatives 
(Histoplasma 
capsulatum yeast 
cells)
Larynx 1 2 Negative Negative
Lymph node 2 2-3 2 Negatives 2 Negatives
Bone Marrow 1 0 Positive Negative
Oral mucosa 1 0 Negative Negative
Nasal mucosa 1 2 Negative Negative
Skin 1 2 Positive Negative
Lung 1 0 Negative Negative
False negatives 
(negative biopsy, 
positive myelogram 
or K39 test)
Stomach 1 0 Negative Negative
Liver 1 0 Negative Negative
Lymph node 2 0 2 Negatives 2 Negatives
Bone Marrow 21 0 21 Negatives 21 Negatives
Table 2 - Results after the exclusion of bone marrow biopsies.
O10 MTB1
Sensitivity 8.33% 58.33%
Specificity 87.50% 100%
Accuracy 40.00% 75%
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immunohistochemical stainings14. Although none of the 
samples of Histoplasma capsulatum had positive results 
with the use of clone MTB1, 25% of them had positive 
results with clone O10, which can lead to misdiagnosis. 
It is imperative to do perform special stainings for fungi, 
such as PAS and Grocott’s methenamine silver, to avoid 
misdiagnosis.
We conclude that immunohistochemical testing with 
the CD1a antigen, clone MTB1, despite the intermediate 
sensitivity observed in this study, can be useful in the 
differential diagnosis of visceral leishmaniasis, helping to 
discriminate leishmania amastigotes from other pathogens 
with similar morphology and cellular debris in different 
samples, except in bone marrow biopsies previously 
decalcified with nitric acid.
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